Multimodal Oncological Therapy Comprising Stents, Brachytherapy
and Regional Chemotherapy for Cholangiocarcinoma

J 2010

Multimodal Oncological Therapy Comprising Stents, Brachytherapy and Regional Chemotherapy for Cholangiocarcinoma

ANDRAŠINA, Tomáš; Vlastimil VÁLEK; Jiří PÁNEK; Zdeněk KALA; Igor KISS et al.

Základní údaje

Originální název

Multimodal Oncological Therapy Comprising Stents, Brachytherapy and Regional Chemotherapy for Cholangiocarcinoma

Autoři

ANDRAŠINA, Tomáš; Vlastimil VÁLEK ; Jiří PÁNEK; Zdeněk KALA; Igor KISS; Štěpán TUČEK a Pavel ŠLAMPA

Vydání

Gut and Liver, 2010, 1976-2283

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30000 3. Medical and Health Sciences

Stát vydavatele

Česká republika

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 0.219

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/10:00051433

Organizační jednotka

Lékařská fakulta

DOI

https://doi.org/10.5009/gnl.2010.4.S1.S82

UT WoS

000281932700013

Klíčová slova anglicky

Cholangiocarcinoma; Brachytherapy; Infusions; Intra-arterial; Stents

Příznaky

Mezinárodní význam

Změněno: 20. 4. 2012 14:58, Mgr. Michal Petr

Anotace

V originále

BACKGROUND/AIMS: To prospectively evaluate our palliative management of unresectable cholangiocarcinoma (CC) treated with tailored multimodal oncological therapy. In total, 78 metal self-expandable stents were placed. Hilar involvement with mass-forming and periductal infiltrating types of CC (84%) was predominant. The average number of percutaneous interventional procedures was 11.61 per patient (range, 4-35). The median overall survival from diagnosis of disease for all patients was 13.5 months . The median overall survival times were 25.2 months and 11.5 months in the IA and IV arms, respectively (p<0.05). The 1-, 2-, and 3-year survival rates in the IA and IV arms were 88.2%, 52.9%, and 10.1% and 43.5%, 25.4, and 0%, respectively.CONCLUSIONS: We could reach acceptable prognosis in patients with unresectable CC using complex tailored oncological therapy. However, the main limitations of prolonging survival are performance status, patient compliance and the maintaining of biliary tract patency.

Citovat

ANDRAŠINA, Tomáš; Vlastimil VÁLEK; Jiří PÁNEK; Zdeněk KALA; Igor KISS; Štěpán TUČEK a Pavel ŠLAMPA. Multimodal Oncological Therapy Comprising Stents, Brachytherapy and Regional Chemotherapy for Cholangiocarcinoma. Gut and Liver. 2010, roč. 4, Suppl.1, s. "S82"-"S88", 7 s. ISSN 1976-2283. Dostupné z: https://doi.org/10.5009/gnl.2010.4.S1.S82.

@article{896048,
   author = {Andrašina, Tomáš and Válek, Vlastimil and Pánek, Jiří and Kala, Zdeněk and Kiss, Igor and Tuček, Štěpán and Šlampa, Pavel},
   article_number = {Suppl.1},
   doi = {https://doi.org/10.5009/gnl.2010.4.S1.S82},
   keywords = {Cholangiocarcinoma; Brachytherapy; Infusions; Intra-arterial; Stents},
   language = {eng},
   issn = {1976-2283},
   journal = {Gut and Liver},
   title = {Multimodal Oncological Therapy Comprising Stents, Brachytherapy and Regional Chemotherapy for Cholangiocarcinoma},
   volume = {4},
   year = {2010}
}

TY  - JOUR
ID  - 896048
AU  - Andrašina, Tomáš - Válek, Vlastimil - Pánek, Jiří - Kala, Zdeněk - Kiss, Igor - Tuček, Štěpán - Šlampa, Pavel
PY  - 2010
TI  - Multimodal Oncological Therapy Comprising Stents, Brachytherapy and Regional Chemotherapy for Cholangiocarcinoma
JF  - Gut and Liver
VL  - 4
IS  - Suppl.1
SP  - "S82"-"S88"
EP  - "S82"-"S88"
SN  - 19762283
KW  - Cholangiocarcinoma
KW  - Brachytherapy
KW  - Infusions
KW  - Intra-arterial
KW  - Stents
N2  - BACKGROUND/AIMS: To prospectively evaluate our palliative management of unresectable cholangiocarcinoma (CC) treated with tailored multimodal oncological therapy. In total, 78 metal self-expandable stents were placed. Hilar involvement with mass-forming and periductal infiltrating types of CC (84%) was predominant. The average number of percutaneous interventional procedures was 11.61 per patient (range, 4-35). The median overall survival from diagnosis of disease for all patients was 13.5 months . The median overall survival times were 25.2 months and 11.5 months in the IA and IV arms, respectively (p<0.05). The 1-, 2-, and 3-year survival rates in the IA and IV arms were 88.2%, 52.9%, and 10.1% and 43.5%, 25.4, and 0%, respectively.CONCLUSIONS: We could reach acceptable prognosis in patients with unresectable CC using complex tailored oncological therapy. However, the main limitations of prolonging survival are performance status, patient compliance and the maintaining of biliary tract patency.
ER  -

ANDRAŠINA, Tomáš; Vlastimil VÁLEK; Jiří PÁNEK; Zdeněk KALA; Igor KISS; Štěpán TUČEK a Pavel ŠLAMPA. Multimodal Oncological Therapy Comprising Stents, Brachytherapy and Regional Chemotherapy for Cholangiocarcinoma. \textit{Gut and Liver}. 2010, roč.~4, Suppl.1, s.~''S82''-''S88'', 7 s. ISSN~1976-2283. Dostupné z: https://doi.org/10.5009/gnl.2010.4.S1.S82.

Přehled o publikaci